

1 ROBERT W. FERGUSON  
 Attorney General  
 2 NOAH GUZZO PURCELL, WSBA #43492  
 Solicitor General  
 3 KRISTIN BENESKI, WSBA #45478  
 First Assistant Attorney General  
 4 COLLEEN M. MELODY, WSBA #42275  
 Civil Rights Division Chief  
 5 ANDREW R.W. HUGHES, WSBA #49515  
 LAURYN K. FRAAS, WSBA #53238  
 6 Assistant Attorneys General  
 TERA M. HEINTZ, WSBA #54921  
 7 (application for admission forthcoming)  
 Deputy Solicitor General  
 8 800 Fifth Avenue, Suite 2000  
 Seattle, WA 98104-3188  
 9 (206) 464-7744

10 **UNITED STATES DISTRICT COURT**  
 11 **EASTERN DISTRICT OF WASHINGTON**

12 STATE OF WASHINGTON, et al.,

13 Plaintiffs,

14 v.

15 UNITED STATES FOOD AND  
 DRUG ADMINISTRATION, et al.,

16 Defendants.

NO. 1:23-cv-03026-TOR

PLAINTIFF STATES' RESPONSE  
 TO DEFENDANTS' MOTION FOR  
 EXTENSION OF TIME

03/07/2023<sup>1</sup>  
 Without Oral Argument

17 \_\_\_\_\_  
 18 <sup>1</sup>Due to the urgency of this matter, the Plaintiff States are filing this  
 19 response well in advance of the March 6, 2023, deadline. *See* ECF No. 18.  
 20 Because the Court's briefing schedule on this motion authorized a response and  
 21 no further briefing, the Plaintiff States understand this motion to now be ripe for  
 22 decision. *Id.*

1 **I. INTRODUCTION**

2 The Plaintiff States oppose Defendants’ Motion for Extension of Time  
3 (ECF No. 16) to respond to the Plaintiff States’ Motion for Preliminary Injunction  
4 (PI Motion) (ECF No. 3). The Plaintiff States moved for preliminary relief to  
5 protect access to critically important abortion and miscarriage care at a time when  
6 access to reproductive health care is under unprecedented attack. The FDA’s  
7 newly-enacted REMS restrictions unnecessarily limit who can prescribe,  
8 dispense, and obtain mifepristone for medication abortion, which unduly restricts  
9 access to this time-sensitive and extremely safe medication, leading to worse  
10 outcomes for patients and creating substantial and continuing burdens on  
11 providers and pharmacies. This is an urgent matter, and Defendants’ request for  
12 an extended briefing and hearing schedule should be denied.

13 **II. ARGUMENT**

14 **A. The Fourteen-Day Time Period Prescribed in the Local Rules**  
15 **Controls**

16 Local Civil Rule 7 provides Defendants with fourteen days to respond to  
17 the Plaintiff States’ PI Motion, i.e., until March 10, 2023. *See* LCivR 7(c)(2)(B),  
18 (b)(3). Extending this deadline requires a showing of “good cause.” Fed. R. Civ.  
19 P. 6(b)(1); *see also* *Algaier v. CMG Mortg., Inc.*, No. 13-CV-0380-TOR,  
20 2014 WL 129286, at \*12 (E.D. Wash. Jan. 14, 2014); *Dysart v. Ames*,

1 No. 13-CV-0261-TOR, 2014 WL 1364961, at \*2 (E.D. Wash. Apr. 7, 2014).

2 Defendants fail to establish good cause for the extension they seek.

3 **B. Plaintiff States Did Not Delay in Moving for a Preliminary Injunction**

4 Defendants assert that the Plaintiff States “delay[ed]” in seeking a  
5 preliminary injunction—thus justifying a departure from the ordinary briefing  
6 schedule. ECF No. 16 at 2. This argument buries the most important facts. The  
7 REMS at the heart of this dispute did not take effect until January 3, 2023, and  
8 this challenge to final agency action was not ripe until that date. 5 U.S.C. § 704.  
9 In the time between the effective date of the REMS and the Plaintiff States’  
10 filings, this coalition of twelve states convened and drafted an 82-page Complaint  
11 and a 34-page PI Motion. In support of these filings, the Plaintiff States submitted  
12 approximately 800 pages of exhibits and evidence, including expert and technical  
13 evidence. Much of this evidence covers the impact of the REMS since its January  
14 2023 effective date—evidence that would have been impossible to provide had  
15 the Plaintiff States filed their PI Motion sooner. In short, the seven weeks to  
16 prepare and file Plaintiff States’ papers cannot be characterized as a “delay”—  
17 much less an “extreme delay”—under these circumstances. To the contrary, the  
18 timeline on which the Plaintiff States filed their Complaint and PI Motion were  
19 consistent with the level of urgency this case presents.

1 **C. An Extension Would Result in Severe Prejudice to Plaintiff States**

2 A delay in hearing the PI Motion will severely prejudice the Plaintiff  
3 States. The 2023 REMS restrictions are harming the Plaintiff States every day  
4 that they remain in effect. In today’s post-*Dobbs* landscape, in which the actions  
5 of anti-abortion state governments have strained access to abortion care even in  
6 states where abortion is a protected right, the 2023 REMS is exacerbating a crisis  
7 in abortion access of unprecedented proportions—warranting swift action by the  
8 Court.

9 Since *Dobbs*, the Plaintiff States have seen a huge influx of out-of-state  
10 patients seeking abortions. Cantrell Decl. ¶¶ 5, 7;<sup>2</sup> Dillon Decl. ¶¶ 8–13. For  
11 example, in January 2023, Planned Parenthood of Greater Washington and  
12 Northern Idaho saw a 75% increase in Idaho patients, as compared with January  
13 2022. Dillon Decl. ¶ 10. “This includes a . . . 90% increase for medication  
14 abortion visits from Idaho.” *Id.* This increased patient volume has led to delays  
15 in abortion care and other consequences, including higher risks of complications,  
16 increased costs, and unnecessary trauma and stress for patients in the Plaintiff  
17 States, as well as increasing burdens on an already overtaxed healthcare system.  
18 *Id.* at ¶¶ 14–22; Godfrey Decl. ¶¶ 28, 31; [FDA’s] Opp’n to Pls.’ Mot. for a  
19 Prelim. Inj., *All. for Hippocratic Med. v. FDA*, No. 2:22-cv-00223-Z (N.D. Tex.  
20 Jan. 13, 2023), ECF No. 28 at 38–39; Compl. ¶ 142. By making mifepristone

21 \_\_\_\_\_  
22 <sup>2</sup>All declaration cites are to the declarations filed at ECF No. 4-1.

1 harder to prescribe, dispense, and obtain, the REMS exacerbates these growing  
2 harms. Gold Decl. ¶¶ 15–16, 27; Godfrey Decl. ¶¶ 17–22; Shih Decl. ¶¶ 21–29;  
3 Colwill Decl. ¶¶ 18–25; Nichols Decl. ¶ 38; Janiak Decl. ¶¶ 15–20; Downing  
4 Decl. ¶¶ 9–16; Henry Decl. ¶¶ 6–8; Lazarus Decl. ¶¶ 17–20; Compl. ¶¶ 136–138.

5 Further, the 2023 REMS works in concert with post-*Dobbs* legislation in  
6 anti-abortion states to limit access to abortion even in states where it is legal. As  
7 medical expert Marji Gold explains:

8 In the current hostile environment surrounding abortion care, which  
9 includes states passing bills that empower ordinary citizens to sue  
10 anyone they deem has “aided and abetted” a person seeking an  
11 abortion, clinicians may be reluctant to become certified and thus be  
12 identified as a person who prescribes mifepristone. Since the REMS  
13 requires certified prescribers to send their signed forms to *each*  
14 certified pharmacy at which they intend to prescribe, clinicians who  
15 wish to provide this care have reason to be concerned that an anti-  
16 abortion staff or pharmacist at a pharmacy might leak the  
17 confidential list and expose them to possible violence and/or civil or  
18 criminal liability. These concerns may be greater in communities  
19 with outspoken anti-abortion members, and thus decrease patient  
20 access to care.

21 Gold Decl. ¶ 18; *see also id.* at ¶ 19 (explaining the particular risk to patients who  
22 hold medical licenses in multiple states, including anti-abortion states); Prager  
Decl. ¶¶ 38–40; Shih Decl. ¶ 25.

For patients seeking to terminate a pregnancy, mere days can make a  
critical difference. The delays in treatment arising from the REMS—whether due  
to a lack of specifically “certified providers” (Godfrey Decl. ¶ 30) or pharmacies  
(Shih Decl. ¶ 27), a lack of access to technology required to e-sign the Patient

1 Agreement Form (*id.* at ¶ 17), or lagging or incomplete REMS-required  
2 paperwork (DasGupta Decl. ¶ 10)—may cause patients to miss the narrow  
3 window for medication abortion. Compl. ¶ 81 (mifepristone is only approved for  
4 use up to 70-days’ gestation); Shih Decl. ¶ 17 (“[D]elaying the process even by  
5 a few days may make [some patients] ineligible to select medication abortion.”);  
6 Colwill Decl. ¶ 24. Even a few days’ delay may force such patients to choose  
7 between undergoing an invasive procedural abortion or carrying an unwanted  
8 pregnancy to term. Compl. ¶ 152 (detailing negative outcomes experienced by  
9 patients who are denied abortions); *id.* at ¶¶ 143–44 (explaining why surgical  
10 abortion may be inappropriate or inaccessible to certain patients).

11 These increasing harms are falling most heavily on those furthest from  
12 healthcare justice, including rural and poor communities that have inferior access  
13 to reproductive health care. Gold Decl. ¶ 23; Janiak Decl. ¶¶ 14, 25–29; Downing  
14 Decl. ¶ 17; Dillon Decl. ¶ 7; Godfrey Decl. ¶¶ 15, 17, 19, 32; Nichols Decl. ¶ 38;  
15 Compl. ¶ 121.

16 Finally, implementing the new REMS requirements has created ongoing  
17 burdens for state healthcare providers, resulting in mounting costs and an ongoing  
18 diversion of resources from patient care and other critical work. University of  
19 Washington personnel, for example, have expended hundreds of hours  
20 implementing the 2023 REMS, with many tasks still outstanding. Compl. ¶ 152;  
21 DasGupta Decl. ¶¶ 15–18; Godfrey Decl. ¶ 35; Prager Decl. ¶¶ 25–36; Reed  
22

1 Decl. ¶¶ 16–17; Singh Decl. ¶¶ 20–21. These harms are occurring now, because  
2 of the 2023 REMS, and they are urgent. Any further delay in addressing them  
3 will continue to prejudice the Plaintiff States.

4 **D. Defendants Would Suffer No Prejudice in Adhering to the Ordinary**  
5 **Briefing Deadlines**

6 By contrast, Defendants will suffer no prejudice if they are required to  
7 respond to the Plaintiff States’ motion on time. The U.S. Department of Justice’s  
8 Consumer Protection Branch has represented the FDA in a number of recent  
9 challenges to its regulation of mifepristone, including its imposition of the  
10 REMS. *See, e.g.*, [FDA’s] Opp’n to Pls.’ Mot. for a Prelim. Inj., *All. for*  
11 *Hippocratic Med. v. FDA*, No. 2:22-cv-00223-Z (N.D. Tex. Jan. 13, 2023),  
12 ECF No. 28 (Consumer Protection Branch defending challenge to FDA’s  
13 approval of mifepristone; preliminary injunction motion pending); *Chelius v.*  
14 *Wright*, No. 1:17-cv-00493-JAO-RT (D. Haw. May 7, 2021), ECF No. 148  
15 (Consumer Protection Branch defending challenge to FDA’s previous version of  
16 REMS; stayed by joint agreement of parties after FDA agreed to re-examine the  
17 REMS); *Am. Coll. of Obstetricians & Gynecologists v. FDA*, 472 F. Supp. 3d  
18 183, 189 (D. Md. 2020) (Consumer Protection Branch defending challenge to  
19 FDA’s previous version of REMS; preliminary injunction granted against FDA).  
20 At this point, lawyers with the Consumer Protection Branch have been litigating  
21 the facts and law surrounding the REMS for years. In light of their familiarity  
22

1 with the issues, and the urgency facing the Plaintiff States, good cause does not  
2 support an extended briefing schedule.

3 **E. The Plaintiff States' PI Motion Should Be Heard as Soon as Possible**

4 In recognition of the urgency of the matter, the Plaintiff States propose to  
5 file a reply in support of their PI Motion within five days instead of the usual  
6 seven, *see* LCivR 7(d)(2)(B), allowing this matter to be fully briefed for a hearing  
7 on March 16, 2023, a date the Court had previously indicated may be available.  
8 Although that hearing date is earlier than the default time period under  
9 Local Rules, it is appropriate under Local Rule 7(i)(2)(C).

10 For all the reasons explained above and in the Plaintiff States' PI Motion,  
11 this case involves an urgent issue, and good cause supports an expedited hearing.  
12 LCivR 7(i)(2)(C)(1). Defendants' request for an extended briefing and hearing  
13 schedule indicates that Defendants oppose the Plaintiff States' request for an  
14 expedited hearing, LCivR 7(i)(2)(C)(2), but as detailed above, Defendants'  
15 request for an extension should be denied. Finally, the Plaintiff States' proposed  
16 March 16 hearing date is twenty days after the Motion for Preliminary Injunction  
17 was filed, and therefore well within the bounds for expedited hearings.  
18 LCivR 7(i)(2)(C)(3). Indeed, under the Plaintiff States' proposed five-day reply  
19 turnaround, briefing will be complete before March 16 without affecting  
20 Defendants' briefing schedule at all.

1 **III. CONCLUSION**

2 For the foregoing reasons, the Plaintiff States respectfully request that the  
3 Court deny Defendants’ motion for an extension of time and require Defendants  
4 to file their response to the Plaintiff States’ PI Motion no later than March 10,  
5 2023, in accordance with the local rules.

6 DATED this 1st day of March 2023.

7 ROBERT W. FERGUSON  
8 Attorney General

9 */s/ Kristin Beneski*

NOAH GUZZO PURCELL, WSBA #43492  
Solicitor General

10 KRISTIN BENESKI, WSBA #45478  
First Assistant Attorney General

11 COLLEEN M. MELODY, WSBA #42275  
Civil Rights Division Chief

12 ANDREW R.W. HUGHES, WSBA #49515  
LAURYN K. FRAAS, WSBA #53238

13 Assistant Attorneys General

14 TERA M. HEINTZ, WSBA #54921

(application for admission forthcoming)  
Deputy Solicitor General

15 800 Fifth Avenue, Suite 2000  
Seattle, WA 98104-3188

16 (206) 464-7744

*Attorneys for Plaintiff State of Washington*

17  
18 ELLEN F. ROSENBLUM  
Attorney General of Oregon

19 */s/ Marc Hull*

20 SANDER MARCUS HULL WSBA #35986  
Senior Assistant Attorney General

21 YOUNGWOO JOH OSB #164105  
Assistant Attorney General

22 Trial Attorneys

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

Tel (971) 673-1880  
Fax (971) 673-5000  
marcus.hull@doj.state.or.us  
youngwoo.joh@doj.state.or.us  
*Attorneys for State of Oregon*

KRIS MAYES  
Attorney General of Arizona

/s/ Daniel C. Barr  
Daniel C. Barr (Arizona No. 010149)\*  
Chief Deputy Attorney General  
Office of the Attorney General of Arizona  
2005 N. Central Ave.  
Phoenix, AZ 85004-1592  
Phone: (602) 542-8080  
Email: Daniel.Barr@azag.gov  
*Attorney for Plaintiff State of Arizona*

PHILIP J. WEISER  
Attorney General of Colorado

/s/ Eric Olson  
ERIC OLSON, CO #36414\*  
Solicitor General  
MICHAEL MCMASTER, CO #42368\*  
Assistant Solicitor General  
Office of the Attorney General  
Colorado Department of Law  
1300 Broadway, 10th Floor  
Denver, CO 80203  
Phone: (720) 508-6000  
*Attorneys for Plaintiff State of Colorado*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

WILLIAM TONG  
Attorney General of Connecticut

*/s/ Joshua Perry*  
\_\_\_\_\_  
Joshua Perry\*  
Solicitor General  
Office of the Connecticut Attorney General  
165 Capitol Ave, Hartford, CT 06106  
Joshua.perry@ct.gov  
(860) 808-5372  
Fax: (860) 808-5387  
*Attorney for Plaintiff State of Connecticut*

KATHLEEN JENNINGS  
Attorney General of Delaware

*/s/ Vanessa L. Kassab*  
\_\_\_\_\_  
VANESSA L. KASSAB\*  
Deputy Attorney General  
Delaware Department of Justice  
820 N. French Street  
Wilmington, DE 19801  
302-683-8899  
vanessa.kassab@delaware.gov  
*Attorney for Plaintiff State of Delaware*

KWAME RAOUL  
Attorney General of Illinois

*/s/ Liza Roberson-Young*  
\_\_\_\_\_  
Liza Roberson-Young\*  
Public Interest Counsel  
Office of the Illinois Attorney General  
100 West Randolph Street  
Chicago, IL 60601  
Phone: (872) 272-0788  
E.RobersonYoung@ilag.gov  
*Attorney for Plaintiff State of Illinois*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

DANA NESSEL  
Attorney General of Michigan  
  
*/s/ Stephanie M. Service*  
Stephanie M. Service (P73305)\*  
Assistant Attorney General  
Michigan Department of Attorney General  
Health, Education & Family  
Services Division  
P.O. Box 30758  
Lansing, MI 48909  
(517) 335-7603  
ServiceS3@michigan.gov  
*Attorney for Plaintiff Attorney General of  
Michigan*

AARON D. FORD  
Attorney General of Nevada  
  
*/s/ Heidi Parry Stern*  
Heidi Parry Stern (Bar. No. 8873)\*  
Solicitor General  
Office of the Nevada Attorney General  
555 E. Washington Ave., Ste. 3900  
Las Vegas, NV 89101  
HStern@ag.nv.gov  
*Attorney for Plaintiff State of Nevada*

RAÚL TORREZ  
Attorney General of New Mexico  
  
*/s/ Aletheia Allen*  
Aletheia Allen\*  
Solicitor General  
New Mexico Office of the Attorney General  
201 Third St. NW, Suite 300  
Albuquerque, NM 87102  
AAllen@nmag.gov  
*Attorney for Plaintiff State of New Mexico*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

PETER F. NERONHA  
Attorney General of Rhode Island

*/s/ Julia C. Harvey*  
\_\_\_\_\_  
JULIA C. HARVEY #10529  
Special Assistant Attorney General  
150 S. Main Street  
Providence, RI 02903  
(401) 274-4400 x2103  
*Attorney for Plaintiff State of Rhode Island*

CHARITY R. CLARK  
Attorney General of Vermont

*/s/ Eleanor L.P. Spottswood*  
\_\_\_\_\_  
ELEANOR L.P. SPOTTSWOOD\*  
Solicitor General  
109 State Street  
Montpelier, VT 05609-1001  
(802)793-1646  
eleanor.spottswood@vermont.gov  
*Attorney for Plaintiff State of Vermont*

*\*Applications for pro hac vice admission  
forthcoming*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

**CERTIFICATE OF SERVICE**

I hereby certify that on March 1, 2023, I electronically filed the foregoing with the Clerk of the Court using the CM/ECF System, which in turn automatically generated a Notice of Electronic Filing (NEF) to all parties in the case who are registered users of the CM/ECF system. The NEF for the foregoing specifically identifies recipients of electronic notice.

DATED this 1st day of March 2023, at Seattle, Washington.

*/s/ Kristin Beneski*  
\_\_\_\_\_  
KRISTIN BENESKI, WSBA #45478  
First Assistant Attorney General